We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Spectral Diagnostics Provides Update on Euphrates Trial

News   Jun 25, 2012

 
Spectral Diagnostics Provides Update on Euphrates Trial
 
 
Advertisement
 

RELATED ARTICLES

Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer

News

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

READ MORE

Olaparib Successfully Treats Prostate Cancers With Genetic Fault in Clinical Trial

News

Results from the PROfound trial have showed that olaparib – a drug called a PARP inhibitor – can be used successfully to treat prostate cancers with a "weakness" in their ability to repair damaged DNA.

READ MORE

Phase 3 Clinical Trial of Belimumab for Lupus Nephritis Reports Positive Results

News

Results from the largest Phase 3 lupus nephritis clinical trial ever conducted were announced, September 16. The study, found positive results of the efficacy and safety of the drug belimumab in patients with active lupus nephritis, a condition that causes inflammation in the kidneys of patients with systemic lupus erythematosus.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE